FDA rejects Public Citizen's demand to pull Meridia

Public Citizen has lost a three-year battle to persuade the FDA to remove Abbott Laboratories' weight-loss drug Meridia from the market. Regulators said that the drug's benefits continue to outweigh the risks of taking it. Public Citizen maintained that Meridia was linked to more than 400 adverse reactions and contributed to the deaths of dozens of patients. "This decision is good news for obese patients and their physicians who are considering pharmacotherapy who may have been alarmed by Public Citizen," said Dr. John Leonard, Abbott's vice president of global medical affairs.

- read this story from the Chicago Tribune for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.